Recent Advances and Challenges in Liquid Biopsy Based Cancer Research

(October 10, 2018)

Sponsored by
Streck logo



Webinar Description:
This webinar will provide an overview of liquid biopsy-based diagnosis and include an overview about nucleic-acid based liquid biopsy approaches in blood and other bodily fluids. The webinar will discuss key challenges for choice of appropriate materials, tubes and pre-analytical sample handling, analytical considerations regarding technologies, quality control, optimization of accuracy and data interpretation strategies. The speaker will delineate the clinical application of liquid biopsy for diagnosis, therapy stratification, therapy and residual disease monitoring in cancer patients and give an outlook on new fields of diagnostic application in cardiovascular diseases and transplantation medicine.

Learning Objectives:

  • Learn about recent developments in liquid biopsy using different matrices and technologies
  • Get to know diverse nucleic-acid-based diagnostic approaches
  • Identify key challenges in the pre-analytical, analytical and post-analytical process
  • Learn about clinical indications for liquid biopsy application
  • Discuss the current status of clinical studies on liquid biopsy in cancer disease
  • Cell-Free DNA BCT is For Research Use Only. Not for use in diagnostic procedures
  • Cell-Free DNA BCT CE is for Export Only. Not for sale in the US


Stefan HoldenriederProf. Dr. med. Stefan Holdenrieder
Prof. Dr. med. Stefan Holdenrieder
Director of the Institute of Laboratory Medicine
German Heart Center of the Technical University Munich
Head of the Munich Biomarker Research Center
Head of the Section “Translational Research” of the Central European Society of Anticancer Drug Research (CESAR)
Secretary of the Board of Directors of the International Society of Oncological BioMarkers (ISOBM)
External Quality Assessment-Scheme Consultant for Tumor Marker ring trials at Instand e.V.
2014 apl. Professor, Clin. Chemistry & Laboratory Medicine, University Bonn
2006 Habilitation for Laboratory Medicine, University Munich
2004 MD thesis, University Munich 2

Patents EP 1064549, US 7229772, US 7759071, WO 2014/131845
Associate Editor Tumor Biology, BMC Cancer, J Lab Med
Reviewer DFG, BMBF, A-Star, JCO, Blood, CCR, IJC, BJC,

Joel LechnerJoel Lechner, MS
Product Manager, Marketing

Joel Lechner earned his MS in Biochemistry from The University of Nebraska at Lincoln. After getting his degree he worked at Streck in Research and Development for nearly a decade. His current role is Product Manager for the Liquid Biopsy product line, which includes Cell-Free DNA BCT® and Cell-Free RNA BCT® as well as Cell-Free DNA Urine Preserve.

(October 10, 2018)